AtaiBeckley

AtaiBeckley is a clinical-stage biopharmaceutical company headquartered in New York and Amsterdam, focused on developing rapid-acting and convenient mental health treatments to transform patient outcomes. Formed through the strategic combination of atai Life Sciences and Beckley Psytech Limited completed in November 2025, the company brings togethe... r world-class science and clinical expertise with a pipeline of investigational psychedelic-based neuroplastogens designed to address urgent unmet needs in mental health. AtaiBeckley's lead program is BPL-003, a novel mebufotenin benzoate nasal spray designed to produce rapid and durable antidepressive effects from a single dose for treatment-resistant depression, which has received Breakthrough Therapy designation from the FDA and is Phase 3-ready. The company's diversified pipeline also includes VLS-01, a DMT buccal film for treatment-resistant depression currently in Phase 2 clinical trials, EMP-01, an oral R-MDMA being evaluated for social anxiety disorder, and a portfolio of novel 5-HT2A receptor agonists, including non-hallucinogenic neuroplastogens, in earlier stages of development. Led by CEO and Co-Founder Dr. Srinivas Rao and an experienced executive team with deep expertise in neuroscience, psychiatry, and drug development, AtaiBeckley aims to create commercially scalable interventional psychiatry therapies that can integrate seamlessly into healthcare systems. The company is publicly traded on NASDAQ under the ticker symbol ATAI.Read More